Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Non-Small Cell Lung Cancer Specialty Channel

Non-Small Cell Lung Cancer
Specialty Channel
News
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
News
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
News
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology
News
07/15/2024
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3...
07/15/2024
Oncology
Conference Coverage
06/26/2024
According to results from the phase 2 RAGNAR study, erdafitinib demonstrated promising clinical activity among pre-treated patients with non-small cell lung cancer (NSCLC) harboring pre-specified FGFR alterations.
According to results from the phase 2 RAGNAR study, erdafitinib demonstrated promising clinical activity among pre-treated patients with non-small cell lung cancer (NSCLC) harboring pre-specified FGFR alterations.
According to results from the...
06/26/2024
Oncology
Conference Coverage
06/20/2024

Stephanie Holland

Stephanie Holland
Primary analysis results from the phase 2 WU-KONG1 study found that sunvozertinib demonstrated promising anti-tumor efficacy and safety among patients with platinum pre-treated locally advanced or metastatic non-small cell lung cancer...
Primary analysis results from the phase 2 WU-KONG1 study found that sunvozertinib demonstrated promising anti-tumor efficacy and safety among patients with platinum pre-treated locally advanced or metastatic non-small cell lung cancer...
Primary analysis results from...
06/20/2024
Oncology
Tony Mok, MD
Conference Coverage
06/17/2024
Tony Mok, MD
According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.
According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.
According to results from the...
06/17/2024
Oncology
News
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
Quiz
06/13/2024
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year...
06/13/2024
Oncology
Conference Coverage
06/13/2024

Stephanie Holland 

Stephanie Holland 
Exploratory results from the phase 3 AEGAN study found that the addition of perioperative durvalumab to neoadjuvant chemotherapy improved efficacy with manageable safety among treatment-naive patients with resectable non-small cell lung...
Exploratory results from the phase 3 AEGAN study found that the addition of perioperative durvalumab to neoadjuvant chemotherapy improved efficacy with manageable safety among treatment-naive patients with resectable non-small cell lung...
Exploratory results from the...
06/13/2024
Oncology
Conference Coverage
06/02/2024

Allison Casey

Allison Casey
According to updated data presented at the 2024 ASCO Annual Meeting, lorlatinib has provided the longest progression-free survival ever reported among patients with advanced ALK-positive non-small cell lung cancer.
According to updated data presented at the 2024 ASCO Annual Meeting, lorlatinib has provided the longest progression-free survival ever reported among patients with advanced ALK-positive non-small cell lung cancer.
According to updated data...
06/02/2024
Oncology

Advertisement

News

News
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
News
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
News
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology
News
07/15/2024
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3...
07/15/2024
Oncology
Conference Coverage
06/26/2024
According to results from the phase 2 RAGNAR study, erdafitinib demonstrated promising clinical activity among pre-treated patients with non-small cell lung cancer (NSCLC) harboring pre-specified FGFR alterations.
According to results from the phase 2 RAGNAR study, erdafitinib demonstrated promising clinical activity among pre-treated patients with non-small cell lung cancer (NSCLC) harboring pre-specified FGFR alterations.
According to results from the...
06/26/2024
Oncology
Conference Coverage
06/20/2024

Stephanie Holland

Stephanie Holland
Primary analysis results from the phase 2 WU-KONG1 study found that sunvozertinib demonstrated promising anti-tumor efficacy and safety among patients with platinum pre-treated locally advanced or metastatic non-small cell lung cancer...
Primary analysis results from the phase 2 WU-KONG1 study found that sunvozertinib demonstrated promising anti-tumor efficacy and safety among patients with platinum pre-treated locally advanced or metastatic non-small cell lung cancer...
Primary analysis results from...
06/20/2024
Oncology
Tony Mok, MD
Conference Coverage
06/17/2024
Tony Mok, MD
According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.
According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.
According to results from the...
06/17/2024
Oncology
News
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
Conference Coverage
06/13/2024

Stephanie Holland 

Stephanie Holland 
Exploratory results from the phase 3 AEGAN study found that the addition of perioperative durvalumab to neoadjuvant chemotherapy improved efficacy with manageable safety among treatment-naive patients with resectable non-small cell lung...
Exploratory results from the phase 3 AEGAN study found that the addition of perioperative durvalumab to neoadjuvant chemotherapy improved efficacy with manageable safety among treatment-naive patients with resectable non-small cell lung...
Exploratory results from the...
06/13/2024
Oncology
Conference Coverage
06/02/2024

Allison Casey

Allison Casey
According to updated data presented at the 2024 ASCO Annual Meeting, lorlatinib has provided the longest progression-free survival ever reported among patients with advanced ALK-positive non-small cell lung cancer.
According to updated data presented at the 2024 ASCO Annual Meeting, lorlatinib has provided the longest progression-free survival ever reported among patients with advanced ALK-positive non-small cell lung cancer.
According to updated data...
06/02/2024
Oncology

Interactive Features

Quiz
06/13/2024
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year...
06/13/2024
Oncology
Quiz
05/29/2024
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the...
05/29/2024
Oncology
Quiz
04/04/2024
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the...
04/04/2024
Oncology
Quiz
03/21/2024
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase...
03/21/2024
Oncology
Quiz
05/16/2023
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with...
05/16/2023
Oncology
Quiz
04/17/2023
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score...
04/17/2023
Oncology
Quiz
04/13/2023
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus...
04/13/2023
Oncology
Quiz
02/15/2023
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to...
02/15/2023
Oncology
Quiz
01/31/2023
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did...
01/31/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement